Melatonin markets in New York finished March firmer, with a modest rise and a late-March weekly uptick of about 0.32%. Early March weakness gave way to supply tightness from regulatory detentions and logistics disruptions, while mid- to late-March shifts around precursor availability and energy costs reinforced momentum. Overall, the month showed positive momentum as constrained inbound flows coincided with steady consumer demand. Import controls and robust retail call-offs left the market oriented toward firmness as March closed. Demand remained strongest in consumer supplements and online channels, where convenient formats and subscription models supported uptake. Gummies and other OTC sleep aids underpinned retail pull, aligned with sleep-health concerns and demographic trends. Pharmaceutical/API procurement remained moderate amid constrained precursor availability and targeted sourcing. Detentions and export curbs on L-tryptophan lifted precursor costs and tightened API supply, underscoring input-driven pressures. The near-term outlook remains firm with upside risk if imports stay tight and precursor flows lag.
Melatonin prices finished March on firmer footing as supply tightness from regulatory controls and logistics disruptions pushed landed costs higher. Overall month-on-month performance was positive as producers and importers navigated constrained inbound flows and sustained consumer melatonin pull.
Demand remained strongest in consumer supplements and online retail channels, where melatonin convenient formats and subscription models drove steady uptake. The consumer supplements/OTC sleep-aid segment, led by gummies and other convenient melatonin formats, continued to underpin retail pull, supported by persistent sleep-related health concerns and demographic trends. Per data, over 30% of U.S. adults report insomnia, and younger cohorts dominate melatonin purchases, with 61% of buyers from Millennials and Gen Z. E-commerce traction was notable: gummies accounted for a large share of melatonin units on major online platforms and promotional subscription discounts in the mid-teens accelerated melatonin call-offs, reinforcing inventory depletion. In contrast, pharmaceutical/API procurement remained moderate as buyers navigated constrained precursor availability and targeted sourcing strategies.
Supply dynamics were central to March’s melatonin price behaviour. Rising Middle East energy prices and elevated melatonin logistics costs increased landed costs and delivery uncertainty. Most consequentially, regulatory measures affecting pharmaceutical-grade L-tryptophan exports late in March lifted precursor costs, affecting melatonin API availability and adding upward pressure to spot melatonin offers. The global concentration of precursor capacity also amplified the impact of export curbs, with a relatively small producer base controlling a large share of global melatonin capacity, per ChemAnalyst data. Together these factors increased input-driven cost pressure across import-dependent melatonin supply chains.
Weekly patterns reflected a market that firmed through March before moderating at month-end. Melatonin prices were broadly stable in very early March, then moved higher through mid-month amid tightened imports and brisk retail demand, with mid-month weekly gains noticeably stronger before trend moderation. By late March, melatonin momentum eased to a smaller week-on-week rise of 0.32%, per weekly assessment data, indicating the market remained constructive but was beginning to reflect some short-term normalization in trade flows and buying patterns.
Looking ahead, the near-term outlook is for melatonin prices to remain firm with moderate upside risk in the coming week, driven by constrained imports from active regulatory detentions, China’s curbs on pharmaceutical-grade L-tryptophan that have lifted precursor costs by around 18% per ChemAnalyst data, steady downstream retail demand in gummies and subscription formats, and elevated energy and logistics costs. Our analysts caution that the melatonin trajectory is subject to market conditions: any easing of import restrictions or a swift improvement in precursor flows could relieve pressure, while continued regulatory tightness or further energy-driven cost increases would sustain upside risk based on current market trends.
